Roche Pharma unveils multiple sclerosis treatment drug Ocrevus in India

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-02-29 11:30 GMT   |   Update On 2024-03-20 11:38 GMT
Advertisement

New Delhi: Roche Pharma India has launched a drug for the treatment of Multiple Sclerosis (MS), expanding its neurology portfolio to cater to unmet needs of patients grappling with the disease.

The company has introduced Ocrevus (Ocrelizumab) which is the first and only approved disease modifying therapy for both Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS).

Patients on Ocrevus have the highest persistence and superior adherence to treatment because of its twice yearly (once every six months) dosing which is preferable for most patients compared to more frequent (monthly) injections.
"The introduction of Ocrevus represents a pivotal moment in the management of multiple sclerosis in India," Roche Pharma India CEO and Managing Director V Simpson Emmanuel said.
Boasting formidable efficacy, streamlined administration, and a long-term safety record, Ocrevus instils fresh optimism in individuals grappling with this formidable neurological condition, he added.
The majority of individuals are diagnosed with multiple sclerosis between the ages of 20 and 40, making the disease a leading cause of non-traumatic disability in younger adults.

Read also: Roche Xolair gets USFDA nod for children, adults with one or more food allergies

Medical Dialogues team had earlier reported that Roche's Elecsys Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) had received Breakthrough Device Designation from the USFDA.

Read also: Roche receives USFDA Breakthrough Device Designation for Multiple Sclerosis test Elecsys NfL

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News